Therapy for Treatment-experienced Patients


TMC114/r in treatment-experienced patients in power 1, 2 and 3: integrated analysis of laboratory parameters 10/17/06

TMC114 provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined week 48 analysis 10/17/06

TMC114/r is well tolerated by treatment-experienced patients in power 1, 2 and 3: integrated clinical safety analysis 10/17/06

Combination of TMC114/ritonavir and TMC125 in patients with multidrug resistant HIV 10/17/06

TMC114/r in treatment-experienced HIV patients in power 3: 24-week efficacy and safety analysis 10/17/06

Improved quality of life in treatment-experienced HIV patients treated with TMC114/r vs control protease inhibitors: results of power 1 and 2 functional assessment of HIV infection (FAHI) 10/17/06

Absence of TMC114 exposure-efficacy and exposure-safety relationships in power 3 10/17/06

Success of rescue therapy with TMC114 in HIV-infected patients who failed multiple ritonavir-boosted protease inhibitor-based regimens 10/17/06

Lower Rate of Abacavir Hypersensitivity Reaction among Black Patients  10/03/06

Liver Toxicity Associated with Ritonavir-boosted Tipranavir  10/03/06

Darunavir/ritonavir plus TMC125 Shows Good Efficacy and Safety in Patients with Resistant HIV   10/03/06

Nevirapine Liver Toxicity Not Linked to Higher CD4 Counts in 2 Studies  10/03/06

Efficacy and Impact on Lipids of Reduced Lopinavir/ritonavir Dosing  10/03/06

Absence of Sex Differences in Fosamprenavir Efficacy and Safety   9/29/06

Lower HAART Adherence Observed Prior to Viral Load "Blips"   9/29/066

MK-0518, Experimental Integrase Inhibitor from Merck, Shows Significant Potency in HIV Patients with Triple-class Resistant Virus   9/29/066

96-week RESIST Data Show Boosted Tipranavir Produces Superior and Durable Treatment Response   9/29/06

HIV Persists in Aged Memory CD4 Cells during 8 Years of Effective HAART   9/29/06




Google_______________



 

 

 

 



 

 

 

 

 


Conference
Main Page